Ipsen acquired all outstanding shares of Clementia for a purchase price of USD 25 per share in cash upfront plus a
contingent value right of USD 6.0 per share related to the multiple osteochondromas indication for a total transaction value of up to USD 1.31bn.
As previously disclosed, in exchange for each share of WP Stewart common stock, AllianceBernstein is paying WP Stewartshareholders USD 12 per share in cash and issuing one transferable
contingent value right entitling the holders to an additional cash payment of USD four per share if the assets under management in the acquired W.P.
In addition to a pro-rata portion of the Purchase Price, stockholders of TheStreet will receive additional consideration in connection with the closing of the merger transaction consisting of, (1) a special cash distribution equal to the cash held by the company immediately prior to the closing less any excluded liabilities as agreed to between the parties; and (2) a
contingent value right, or CVR, which will entitle each holder to receive a pro-rata portion of the expected release of funds from the outstanding escrow agreements entered into by the company in connection with the sale of each its RateWatch and BoardEx/TheDeal businesses.
In conjunction, Dyax shareholders may receive additional value through a non-tradable
contingent value right that will pay USD4.00 in cash per Dyax share upon approval of DX-2930 in hereditary angioedema (HAE), representing a potential additional USD646m in aggregate contingent consideration.
Stewart common stock, AllianceBernstein is paying WP Stewart shareholders USD12 per share in cash and issuing one transferable
contingent value right entitling the holders to an additional cash payment of USD4.00 per share if the assets under management in the acquired WP Stewart investment services reach USD5bn on or before the third anniversary of the closing, it said.
According to TST, in addition to a pro-rata portion of the Purchase Price, stockholders of TST will receive additional consideration in connection with the closing of the merger transaction consisting of, a special cash distribution equal to the cash held by TST immediately prior to the closing less any excluded liabilities as agreed to between the parties; and a
contingent value right, or CVR, which will entitle each holder to receive a pro-rata portion of the expected release of funds from the outstanding escrow agreements entered into by TST in connection with the sale of each its RateWatch and BoardEx/TheDeal businesses.
Upon the closing of the transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one
contingent value right for each share of Aratana common stock.
Shareholders will also receive one
Contingent Value Right per share of Birner common stock owned.
Additionally, Actavis expects up to approximately USD360m in a
Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.
